[[abstract]]BACKGROUND AND AIMS: Absence or low anti-hepatitis B (HBV) surface antibody (anti-HBs) is associated with increased risk of HBV reactivation in lymphoma patients with resolved HBV infection receiving rituximab-containing chemotherapy. Quantification of anti-HBV core antibody (anti-HBc) is a new marker associated with the natural history and treatment response of chronic HBV infection. This study investigated whether baseline anti-HBc and anti-HBs levels may better predict HBV reactivation. METHODS: We prospectively measured the HBV DNA levels of lymphoma patients with resolved HBV infection receiving rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-based chemotherapy and started antiviral therapy upon HB...
Background/Aims: Tumor necrosis factor-? (TNF-?) inhibitors and ustekunimab are widely used in autoi...
AbstractBackgroundOccult hepatitis B infection (OBI) is characterized by negative hepatitis B surfac...
[[abstract]]Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with 'resolved' HBV infe...
[[abstract]]BACKGROUND AND AIMS: Absence or low anti-hepatitis B (HBV) surface antibody (anti-HBs) i...
[[abstract]]Background and Aims: Prophylactic antiviral therapy was recommended to prevent HBV react...
AIM: To present the characteristics and the course of a series of anti- hepatitis B virus core antib...
Background: Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used ...
Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with "resolved" HBV infect...
BACKGROUND: Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used ...
[[abstract]]Background and Aims: Hepatitis B virus (HBV) reactivation can occur to 10–40% of lymphom...
Rituximab promotes strong immunosuppression leading to a high risk of hepatitis B reactivation (HBV-...
Hepatitis B virus reactivation (HBVr) can develop in HBV surface antigen (HBsAg) positive or HBsAg-n...
Background/purpose: The predictors of off-therapy response in patients treated with neucleos(t)ide a...
Background: Occult hepatitis B infection (OBI) is characterized by negative hepatitis B surface anti...
Background/Aim: Patients with an occult hepatitis B virus (HBV) infection undergoing deep immunosupp...
Background/Aims: Tumor necrosis factor-? (TNF-?) inhibitors and ustekunimab are widely used in autoi...
AbstractBackgroundOccult hepatitis B infection (OBI) is characterized by negative hepatitis B surfac...
[[abstract]]Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with 'resolved' HBV infe...
[[abstract]]BACKGROUND AND AIMS: Absence or low anti-hepatitis B (HBV) surface antibody (anti-HBs) i...
[[abstract]]Background and Aims: Prophylactic antiviral therapy was recommended to prevent HBV react...
AIM: To present the characteristics and the course of a series of anti- hepatitis B virus core antib...
Background: Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used ...
Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with "resolved" HBV infect...
BACKGROUND: Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used ...
[[abstract]]Background and Aims: Hepatitis B virus (HBV) reactivation can occur to 10–40% of lymphom...
Rituximab promotes strong immunosuppression leading to a high risk of hepatitis B reactivation (HBV-...
Hepatitis B virus reactivation (HBVr) can develop in HBV surface antigen (HBsAg) positive or HBsAg-n...
Background/purpose: The predictors of off-therapy response in patients treated with neucleos(t)ide a...
Background: Occult hepatitis B infection (OBI) is characterized by negative hepatitis B surface anti...
Background/Aim: Patients with an occult hepatitis B virus (HBV) infection undergoing deep immunosupp...
Background/Aims: Tumor necrosis factor-? (TNF-?) inhibitors and ustekunimab are widely used in autoi...
AbstractBackgroundOccult hepatitis B infection (OBI) is characterized by negative hepatitis B surfac...
[[abstract]]Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with 'resolved' HBV infe...